PKM2

Sitryx nominates SYX-5219 a novel, oral and targeted PKM2 activator for clinical development in atopic dermatitis

Retrieved on: 
星期三, 四月 10, 2024
CTA, PKM2, Partnership, Patient, Metabolism, Lilly, Inflammation, Immune system, Atopic dermatitis, Therapy

SYX-5219 has the potential to address a broad range of inflammatory diseases and will advance into the clinic for the treatment of atopic dermatitis, the most common inflammatory skin disease.

Key Points: 
  • SYX-5219 has the potential to address a broad range of inflammatory diseases and will advance into the clinic for the treatment of atopic dermatitis, the most common inflammatory skin disease.
  • SYX-5219 offers first-in-class potential as an oral, targeted, disease-modifying anti-inflammatory therapy, targeting a critical enzyme that regulates cell metabolism called pyruvate kinase M2 (PKM2).
  • Iain Kilty, Chief Scientific Officer of Sitryx, commented: “The nomination of SYX-5219 as our first clinical development candidate for atopic dermatitis is a hugely exciting development for Sitryx and an important milestone as we transition to a clinical-stage company.
  • The team has generated a strong preclinical data package that builds on the scientific community’s growing understanding of PKM2 and its role in the pathogenesis of atopic dermatitis.

HPV's Hidden Hand: New Study by Pusan National University Scientists Reveals Key Details in Head and Neck Cancer Microenvironment

Retrieved on: 
星期三, 二月 28, 2024
School, Neoplasm, Incidence, PKM2, Viral, Virology, Informatics, Assistant, Throat, Growth, Health informatics, Human papillomavirus infection, Branches of microbiology, Mouth, RNA, PKM, Tumor microenvironment, B cell, Ephrin, Patient, Glomus tumor, Journal, Tobacco, Medicine, Pusan National University, HPV, HNSCC, Head, Research, Nose, Cancer, EPHA2, Vaccine

BUSAN, South Korea, Feb. 28, 2024 /PRNewswire/ -- Head and neck squamous cell carcinoma (HNSCC) is a type of cancer that affects the mucous membranes of the mouth, nose, and throat. HNSCC is typically associated with tobacco exposure, alcohol abuse, and viral infections. The links between human papillomavirus (HPV) infection status and the molecular characteristics of HNSCC are not clearly defined.

Key Points: 
  • BUSAN, South Korea, Feb. 28, 2024 /PRNewswire/ -- Head and neck squamous cell carcinoma (HNSCC) is a type of cancer that affects the mucous membranes of the mouth, nose, and throat.
  • The links between human papillomavirus (HPV) infection status and the molecular characteristics of HNSCC are not clearly defined.
  • Therefore, the HPV infection could be considered a criterion for developing treatment strategies, thereby enabling precision medicine tailored to the patient's condition!
  • Title of original paper: Deciphering Head and Neck Cancer Microenvironment: Single–Cell and Spatial Transcriptomics Reveals Human Papillomavirus–Associated Differences

Agios Reports Fourth Quarter and Full Year 2021 Financial Results

Retrieved on: 
星期四, 二月 24, 2022
Workforce, Security (finance), Food, ID, COVID-19, Myelodysplastic syndrome, SG, Private Securities Litigation Reform Act, R, Thalassemia, Research, Genetics, Risk, European Medicines Agency, Â, SEC, Hemolytic anemia, Initiate, Sale, Disease, U.S. Securities and Exchange Commission, Pyruvate kinase deficiency, Treatment, Leadership, General officer, Goal, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pyruvate kinase, NASDAQ, Administration, Sickle cell disease, PKM2, EMA, Patient, MDS, GLOBE, PAH, Income, Investor, Positivity, Research and development, RISE, ASH, FDA, Marketing, Patent, Anemia, PK, Society, Pharmaceutical industry, Vaccine, Video game, EU

CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today reported business highlights and financial results for the fourth quarter and year ended Dec. 31, 2021.

Key Points: 
  • Research and Development (R&D) Expenses: R&D expenses for continuing operations were$73.3 million for the fourth quarter of 2021 compared to$59.4 millionfor the fourth quarter of 2020, and$257 millionfor the year endedDec.
  • Selling, General and Administrative (SG&A) Expenses: SG&A expenses for continuing operations were$31.5 millionfor the fourth quarter of 2021 compared to $25.9 million for the fourth quarter of 2020, and $121.4 millionfor the year endedDec.
  • Net Loss: Net loss was$98.6 million for the fourth quarter of 2021 compared to a net loss of$84.5 millionfor the fourth quarter of 2020, and $356.5 millionfor the year endedDec.
  • Agios will host a conference call and live webcast with slides today at8:00 a.m. ETto discuss fourth quarter and year end 2021 financial results and recent business activities.

Cutting off liver cancer's nutrient supply chain

Retrieved on: 
星期四, 二月 3, 2022
Growth, Laboratory, Liver cancer, Neoplasm, Liver, Nobel Prize, Brain, Skin, CSHL, Nutrient, Stony Brook University, Research, Glioblastoma, Cancer, Cold Spring Harbor Laboratory, Cystic fibrosis, Biomedical Research, Cancer research, Genetic code, Student, World Health Organization, Asos, PKM2, Neuroscience, Education, SPRING, World, Protein, Multimedia, RNA, Ionis Pharmaceuticals, Pharmaceutical industry, Dietary supplement, Krainer

ASOs are promising for this type of cancer because after injecting them under the skin, the body would send them directly to the liver.

Key Points: 
  • ASOs are promising for this type of cancer because after injecting them under the skin, the body would send them directly to the liver.
  • The liver cancer would be prevented from growing and spreading to other organs.
  • This strategy also has another benefit, as healthy liver cells do not make the same RNA that ASOs would target in liver cancer cells.
  • Voss says, "Being able to deliver this therapy directly to the liver, without impacting normal liver cells, could provide a more effective, safer option to treat liver cancer in the future."

Tolero Pharmaceuticals Submits Investigational New Drug Application for Experimental PKM2 Activator TP-1454

Retrieved on: 
星期二, 五月 19, 2020
Metabolism, Enzymes, PKM2, Branches of biology, Pyruvate kinase, Oncology, Biochemistry, Biology, Tumor M2-PK

SALT LAKE CITY, Utah, May 19, 2020 /PRNewswire/ --Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its investigational small-molecule pyruvate kinase M2 isoform (PKM2) activator, TP-1454.

Key Points: 
  • SALT LAKE CITY, Utah, May 19, 2020 /PRNewswire/ --Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its investigational small-molecule pyruvate kinase M2 isoform (PKM2) activator, TP-1454.
  • "TP-1454 will be the first PKM2 activator to be tested in cancer patients, representing a novel mechanism that aims to target the underlying metabolics driving tumor growth and anti-cancer immune suppression.
  • We look forward to building our understanding of the potential role of PKM2 activation in the treatment of solid tumors."
  • TP-1454 is an investigational oral pyruvate kinase M2 isoform (PKM2) activator, that will be evaluated in a Phase 1/1b study in patients with advanced metastatic or progressive solid tumors.

Tolero Pharmaceuticals Presents Findings from Preclinical Studies Evaluating Investigational Agents TP-1287 in Prostate Cancer Models and TP-1454 in Colorectal Cancer Models

Retrieved on: 
星期二, 十月 29, 2019
Metabolism, Enzymes, PKM2, Pyruvate kinase, Oncology

TP-1454 is an investigational oral pyruvate kinase M2 isoform (PKM2) activator, under preclinical evaluation in cell-based and animal models of solid tumors.

Key Points: 
  • TP-1454 is an investigational oral pyruvate kinase M2 isoform (PKM2) activator, under preclinical evaluation in cell-based and animal models of solid tumors.
  • Tolero Pharmaceuticals is a clinical-stage biopharmaceutical company researching and developing treatments to improve and extend the lives of patients with hematological and oncological diseases.
  • Any forward-looking statements set forth in this press release speak only as of the date of this press release.
  • Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice.